Focusing on Personalized Medicine, Pfizer Reports PGx Data for Several Oncologics at ASCO
June 09, 2010
Focusing on Personalized Medicine, Pfizer Reports PGx Data for Several Oncologics at ASCO
The slew of PGx abstracts presented by the drug giant at the annual oncology meeting highlighted its “focused approach to cancer drug development through the identification and validation of molecular targets,” Pfizer said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders
March 21, 2012 / Pharmacogenomics Reporter - Genomic Health Updates Analysts on Companion Dx Pipeline, New Education Campaign
November 10, 2010 / Pharmacogenomics Reporter - Lab21 Offering Companion Testing to Personalize ALK Inhibitors for NSCLC Patients
February 22, 2012 / Pharmacogenomics Reporter - Boehringer Ingelheim to Present New Data on PGx NSCLC Drug Afatinib at ASCO Annual Meeting
June 1, 2011 / Pharmacogenomics Reporter - Pfizer, Abbott Plan Parallel Filing for FDA Approval of NSCLC Drug Crizotinib, FISH Test
January 19, 2011 / Pharmacogenomics Reporter